Sernova Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Sernova is gedaald met een gemiddeld jaarlijks tempo van -49.6%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-49.6%

Groei van de winst

-41.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	n/a
Nettomarge	n/a
Laatste winstupdate	31 Jul 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Sernova geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:SEOV.F Opbrengsten, kosten en inkomsten (CAD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Jul 24	-39	9	30
30 Apr 24	-41	9	33
31 Jan 24	-41	10	32
31 Oct 23	-39	8	32
31 Jul 23	-36	8	29
30 Apr 23	-31	8	24
31 Jan 23	-27	7	21
31 Oct 22	-24	8	17
31 Jul 22	-18	7	12
30 Apr 22	-14	5	9
31 Jan 22	-11	4	7
31 Oct 21	-7	2	5
31 Jul 21	-6	2	3
30 Apr 21	-5	2	3
31 Jan 21	-5	2	3
31 Oct 20	-5	3	3
31 Jul 20	-6	3	3
30 Apr 20	-6	3	3
31 Jan 20	-5	3	2
31 Oct 19	-4	2	2
31 Jul 19	-3	1	2
30 Apr 19	-3	1	2
31 Jan 19	-4	1	2
31 Oct 18	-4	1	2
31 Jul 18	-4	1	2
30 Apr 18	-3	1	2
31 Jan 18	-3	1	2
31 Oct 17	-3	1	2
31 Jul 17	-2	1	1
30 Apr 17	-2	1	1
31 Jan 17	-2	1	1
31 Oct 16	-2	1	1
31 Jul 16	-3	1	2
30 Apr 16	-3	1	2
31 Jan 16	-3	1	2
31 Oct 15	-3	1	2
31 Jul 15	-3	1	2
30 Apr 15	-3	1	2
31 Jan 15	-3	1	2
31 Oct 14	-3	1	2
31 Jul 14	-3	1	2
30 Apr 14	-2	1	2

Kwaliteitswinsten: SEOV.F is momenteel verliesgevend.

Groeiende winstmarge: SEOV.F is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SEOV.F is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 49.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SEOV.F over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SEOV.F is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van SEOV.F zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Sernova Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden